Latest
Amgen gets approvals for BeiGene deal, Nplate drug
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Latest
Amgen gets go-ahead on two drugs
Regulators handed Amgen two victories for its drug portfolio, granting the Thousand Oaks biotech giant approval to treat a wider range of patients with osteoporosis and blood disorders. The U.S. Food and Drug Administration approved the use of Amgen’s immune thrombocytopenia drug Nplate for earlier use in adults Oct. 18, allowing it to be given Read More →